FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406874820> ?p ?o ?g. }

• W2406874820 endingPage "456.e1" @default.
• W2406874820 startingPage "448" @default.
• W2406874820 abstract "Background & AimsWe performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.MethodsWe enrolled 161 treatment-naïve or previously treated patients infected with HCV genotypes 1 or 3 with or without compensated cirrhosis at 2 centers in New Zealand, from September 2014 through March 2015. All patients received sofosbuvir (400 mg) and velpatasvir (100 mg) plus GS-9857 (100 mg) once daily. The primary efficacy end point was sustained virologic response at 12 weeks after therapy (SVR12). The duration of therapy was determined by baseline patient characteristics: 4 or 6 weeks for treatment-naïve patients without cirrhosis, 6 weeks for treatment-naïve patients with cirrhosis, and 6 or 8 weeks for treatment-experienced patients with or without cirrhosis.ResultsFour weeks of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in 4 of 15 (27%) treatment-naïve patients with HCV genotype 1 without cirrhosis. Six weeks of this combination produced a SVR12 in 14 of 15 (93%) treatment-naïve patients with HCV genotype 1 without cirrhosis, in 13 of 15 (87%) treatment-naïve genotype 1 patients with cirrhosis, in 15 of 18 (83%) treatment-naïve patients with HCV genotype 3 with cirrhosis, and in 20 of 30 (67%) patients with HCV genotype 1 who had failed an all-oral regimen of 2 or more direct-acting antiviral agents. Eight weeks of the drug combination produced an SVR12 in 17 of 17 (100%) patients with HCV genotype 1, in 19 of 19 (100%) patients with HCV genotype 3 and cirrhosis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) patients with HCV genotype 1 who had failed protease inhibitor−based triple therapy, and in 4 of 4 (100%) patients with HCV genotype 3 who had failed an all-oral regimen of ≥2 direct-acting antiviral agents. The most common reported adverse events were headache, nausea, and fatigue.ConclusionsEight weeks of treatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections, including those with compensated cirrhosis. ClinicalTrials.gov, Number: NCT02202980. We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection. We enrolled 161 treatment-naïve or previously treated patients infected with HCV genotypes 1 or 3 with or without compensated cirrhosis at 2 centers in New Zealand, from September 2014 through March 2015. All patients received sofosbuvir (400 mg) and velpatasvir (100 mg) plus GS-9857 (100 mg) once daily. The primary efficacy end point was sustained virologic response at 12 weeks after therapy (SVR12). The duration of therapy was determined by baseline patient characteristics: 4 or 6 weeks for treatment-naïve patients without cirrhosis, 6 weeks for treatment-naïve patients with cirrhosis, and 6 or 8 weeks for treatment-experienced patients with or without cirrhosis. Four weeks of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in 4 of 15 (27%) treatment-naïve patients with HCV genotype 1 without cirrhosis. Six weeks of this combination produced a SVR12 in 14 of 15 (93%) treatment-naïve patients with HCV genotype 1 without cirrhosis, in 13 of 15 (87%) treatment-naïve genotype 1 patients with cirrhosis, in 15 of 18 (83%) treatment-naïve patients with HCV genotype 3 with cirrhosis, and in 20 of 30 (67%) patients with HCV genotype 1 who had failed an all-oral regimen of 2 or more direct-acting antiviral agents. Eight weeks of the drug combination produced an SVR12 in 17 of 17 (100%) patients with HCV genotype 1, in 19 of 19 (100%) patients with HCV genotype 3 and cirrhosis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) patients with HCV genotype 1 who had failed protease inhibitor−based triple therapy, and in 4 of 4 (100%) patients with HCV genotype 3 who had failed an all-oral regimen of ≥2 direct-acting antiviral agents. The most common reported adverse events were headache, nausea, and fatigue. Eight weeks of treatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections, including those with compensated cirrhosis. ClinicalTrials.gov, Number: NCT02202980." @default.
• W2406874820 created "2016-06-24" @default.
• W2406874820 creator A5009520658 @default.
• W2406874820 creator A5024710603 @default.
• W2406874820 creator A5028045704 @default.
• W2406874820 creator A5034057831 @default.
• W2406874820 creator A5045967483 @default.
• W2406874820 creator A5048879163 @default.
• W2406874820 creator A5064179616 @default.
• W2406874820 creator A5065052188 @default.
• W2406874820 creator A5088842832 @default.
• W2406874820 date "2016-09-01" @default.
• W2406874820 modified "2023-10-01" @default.
• W2406874820 title "Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections" @default.
• W2406874820 cites W1664760337 @default.
• W2406874820 cites W1871242518 @default.
• W2406874820 cites W2009027044 @default.
• W2406874820 cites W2016807153 @default.
• W2406874820 cites W2022899644 @default.
• W2406874820 cites W2043566947 @default.
• W2406874820 cites W2075646129 @default.
• W2406874820 cites W2124151787 @default.
• W2406874820 cites W2131771319 @default.
• W2406874820 cites W2139252405 @default.
• W2406874820 cites W2163028749 @default.
• W2406874820 cites W2216086010 @default.
• W2406874820 cites W2266909385 @default.
• W2406874820 cites W2289667014 @default.
• W2406874820 cites W2292090508 @default.
• W2406874820 cites W2295408863 @default.
• W2406874820 cites W2320330796 @default.
• W2406874820 cites W2406248587 @default.
• W2406874820 cites W2490691249 @default.
• W2406874820 cites W2518050365 @default.
• W2406874820 doi "https://doi.org/10.1053/j.gastro.2016.05.021" @default.
• W2406874820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27240903" @default.
• W2406874820 hasPublicationYear "2016" @default.
• W2406874820 type Work @default.
• W2406874820 sameAs 2406874820 @default.
• W2406874820 citedByCount "57" @default.
• W2406874820 countsByYear W24068748202016 @default.
• W2406874820 countsByYear W24068748202017 @default.
• W2406874820 countsByYear W24068748202018 @default.
• W2406874820 countsByYear W24068748202019 @default.
• W2406874820 countsByYear W24068748202020 @default.
• W2406874820 countsByYear W24068748202021 @default.
• W2406874820 countsByYear W24068748202022 @default.
• W2406874820 countsByYear W24068748202023 @default.
• W2406874820 crossrefType "journal-article" @default.
• W2406874820 hasAuthorship W2406874820A5009520658 @default.
• W2406874820 hasAuthorship W2406874820A5024710603 @default.
• W2406874820 hasAuthorship W2406874820A5028045704 @default.
• W2406874820 hasAuthorship W2406874820A5034057831 @default.
• W2406874820 hasAuthorship W2406874820A5045967483 @default.
• W2406874820 hasAuthorship W2406874820A5048879163 @default.
• W2406874820 hasAuthorship W2406874820A5064179616 @default.
• W2406874820 hasAuthorship W2406874820A5065052188 @default.
• W2406874820 hasAuthorship W2406874820A5088842832 @default.
• W2406874820 hasConcept C126322002 @default.
• W2406874820 hasConcept C203014093 @default.
• W2406874820 hasConcept C2522874641 @default.
• W2406874820 hasConcept C2776408679 @default.
• W2406874820 hasConcept C2776455275 @default.
• W2406874820 hasConcept C2777214474 @default.
• W2406874820 hasConcept C2778390639 @default.
• W2406874820 hasConcept C2780040827 @default.
• W2406874820 hasConcept C2781413609 @default.
• W2406874820 hasConcept C71924100 @default.
• W2406874820 hasConcept C90924648 @default.
• W2406874820 hasConceptScore W2406874820C126322002 @default.
• W2406874820 hasConceptScore W2406874820C203014093 @default.
• W2406874820 hasConceptScore W2406874820C2522874641 @default.
• W2406874820 hasConceptScore W2406874820C2776408679 @default.
• W2406874820 hasConceptScore W2406874820C2776455275 @default.
• W2406874820 hasConceptScore W2406874820C2777214474 @default.
• W2406874820 hasConceptScore W2406874820C2778390639 @default.
• W2406874820 hasConceptScore W2406874820C2780040827 @default.
• W2406874820 hasConceptScore W2406874820C2781413609 @default.
• W2406874820 hasConceptScore W2406874820C71924100 @default.
• W2406874820 hasConceptScore W2406874820C90924648 @default.
• W2406874820 hasIssue "3" @default.
• W2406874820 hasLocation W24068748201 @default.
• W2406874820 hasOpenAccess W2406874820 @default.
• W2406874820 hasPrimaryLocation W24068748201 @default.
• W2406874820 hasRelatedWork W2008996336 @default.
• W2406874820 hasRelatedWork W2153753874 @default.
• W2406874820 hasRelatedWork W2319637145 @default.
• W2406874820 hasRelatedWork W2349205003 @default.
• W2406874820 hasRelatedWork W2494553535 @default.
• W2406874820 hasRelatedWork W2942541802 @default.
• W2406874820 hasRelatedWork W3119724568 @default.
• W2406874820 hasRelatedWork W4255937627 @default.
• W2406874820 hasRelatedWork W4289815992 @default.
• W2406874820 hasRelatedWork W4360862229 @default.
• W2406874820 hasVolume "151" @default.
• W2406874820 isParatext "false" @default.
• W2406874820 isRetracted "false" @default.
• W2406874820 magId "2406874820" @default.

• next